代偿性肝硬化患者胃肿瘤内镜黏膜下剥离术的疗效与安全性:倾向性评分匹配病例对照研究
本研究在2005年1月至2014年12月间,对158例代偿性肝硬化胃肿瘤患者与倾向性评分匹配的158例非肝硬化患者进行对比,发现两组整块切除率(96.8%)、治愈性切除率(89.9%)及不良事件率无显著差异。肝硬化组死亡风险显著高于非肝硬化组(HR 3.52,95%CI 1.35-9.23,P=0.01),但无肝细胞癌的肝硬化患者死亡风险无统计学显著差异(HR 2.14,95%CI 0.72-6.39,P=0.171)。
要点
- 代偿性肝硬化患者胃上皮肿瘤行ESD的整块切除率96.8%、治愈性切除率89.9%,与非肝硬化组无显著差异。
- 肝硬化组出血率10.1%、穿孔率1.9%,与非肝硬化组相比无显著差异。
- 肝硬化组死亡风险显著高于非肝硬化组(HR 3.52,95%CI 1.35-9.23,P=0.01),但无HCC者无统计学显著差异。
核心结论
- 在代偿性肝硬化患者中,尤其是无肝细胞癌者,胃上皮肿瘤的ESD可安全有效地进行,疗效与非肝硬化患者相当,且不引起肝功能恶化。
研究设计与样本
- 倾向性评分匹配病例对照研究,纳入2005年1月至2014年12月在一家三级医疗机构接受胃肿瘤ESD的158例肝硬化患者,并以年龄、性别、组织学、肿瘤位置和病变大小匹配158例非肝硬化患者作为对照组。
主要发现
- 肝硬化组整块切除率96.8%、治愈性切除率89.9%,与非肝硬化组相比无显著差异。
- 肝硬化组出血率10.1%、穿孔率1.9%,与非肝硬化组相比无显著差异。
- 中位手术时间肝硬化组25.0分钟 vs 非肝硬化组23.0分钟,两组相当。
- 生存分析显示肝硬化患者死亡风险显著高于非肝硬化患者(HR 3.52;95%CI 1.35-9.23;P=0.01)。
- 无肝细胞癌的肝硬化患者与非肝硬化组相比死亡风险无统计学显著差异(HR 2.14;95%CI 0.72-6.39;P=0.171)。
临床怎么用
- 作者认为,对于代偿性肝硬化患者,尤其是无肝细胞癌者,胃上皮肿瘤的ESD可安全有效地进行,疗效与非肝硬化患者相当,且不引起肝功能恶化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The clinical outcomes of endoscopic submucosal dissection (ESD) for gastric neoplasms in liver cirrhosis patients have not been adequately reported, leading to clinician concerns about adverse events, including bleeding and the deterioration of liver function. We compared the efficacy and safety of ESD between cirrhosis and noncirrhosis patients. METHODS: Between January 2005 and December 2014, 158 cirrhosis patients underwent ESD for gastric neoplasms at a tertiary medical institution. Their clinical outcomes were compared with those of a propensity score-matched control group (158 patients) selected from noncirrhosis patients, using age, sex, histology, tumor location, and lesion size as variables. RESULTS: En bloc resection (96.8%), curative resection (89.9%), and adverse event (bleeding [10.1%] and perforation [1.9%]) rates in the cirrhosis group did not differ significantly from those in the noncirrhosis group. The median procedure time (25.0 vs 23.0 minutes) was also comparable between the groups. In a survival analysis cirrhosis patients exhibited a significantly higher mortality risk than noncirrhosis patients (hazard ratio [HR], 3.52; 95% confidence interval [CI], 1.35-9.23; P = .01). Cirrhosis patients without hepatocellular carcinoma (HCC) showed no statistically significant difference in mortality compared with the noncirrhosis group (HR, 2.14; 95% CI, .72-6.39; P = .171). Three of 153 patients (2%) exhibited a deterioration of prognosis from Child-Pugh class A to B. CONCLUSIONS: In compensated cirrhosis patients, especially those without HCC, ESD for gastric epithelial neoplasms can be performed with safety and efficacy comparable with that in noncirrhosis patients, without deterioration in liver function.
引用
- Choi YK, Ahn JY, Kim DH, et al. Efficacy and safety of endoscopic submucosal dissection for gastric neoplasms in patients with compensated liver cirrhosis: a propensity score-matched case-control study. Gastrointest Endosc. 2018. PMID: 29410022. doi:10.1016/j.gie.2018.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。